

Confirmation No. 2382

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. GMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete If Known

Application Number	10/734,917
Filing Date	December 12, 2003
First Named Inventor	David James Dooley, et al.
Art Unit	1621
Examiner Name	Deborah D. Carr
Attorney Docket Number	PC25870A

Examiner Initials*	Cite No.*	U. S. PATENT DOCUMENTS		Page, Column, Line, Where Relevant Passages or Relevant Figures Appear
		Document Number Number-Kbd Code* (If known)	Publication Date MM-DD-YYYY	
✓	US-5,670,539	09-23-1997	Mary Ann Richardson	
✓	US-5,919,823	07-06-1999	Mary Ann Richardson	
✓	US-6,117,908	09-12-2000	Paul L. R. Andrews, et al.	
✓	US-6,127,418	10-03-2000	Lionel Bueno, et al.	
✓	US-6,248,363 B1	06-19-2001	Maheb V. Patel, et al.	
✓	US-6,309,663 B1	10-30-2001	Maheb V. Patel, et al.	
✓	US-6,310,098 B1	10-30-2001	Thomas J. Gutuso, Jr.	
✓	US-6,372,792 B1	04-16-2002	Guy Chouinard	
✓	US-2002-0035057 A1	03-21-2002	Virginia Pact Richter, et al.	
✓	US-2002-0037926 A1	03-28-2002	Nancy C. Lan	
✓	US-2002/0072538 A1	06-13-2002	Bertrand L. Chenard, et al.	
✓	US-2002/0099013 A1	07-25-2002	Thomas Piccarillo, et al.	
✓	US-2002/0099092 A1	07-25-2002	David Clive Blakemore, et al.	
✓	US-2002/0165246 A1	11-07-2002	Andrew Holman	
✓	US-2003/0144214 A1	07-31-2003	David Clive Blakemore, et al.	
✓	US-			

Examiner Initials*	Cite No.*	FOREIGN PATENT DOCUMENTS		Page, Column, Line, Where Relevant Passages Or Relevant Figures Appear
		Foreign Patent Document Country Code* Number* (Ind Code* (If known))	Publication Date MM-DD-YYYY	
✓	WO 01/13904 A2	03-01-2001	Ortho-McNeil Pharmaceutical Inc.	
✓	WO 01/45714 A2	06-28-2001	Glaxo Group Limited	
✓	WO 02/34237 A1	05-02-2002	New River Pharmaceuticals Inc.	
✓	WO 03/061656 A1	07-31-2003	Endo Pharmaceuticals Inc.	
✓	DE 198 02 327 A1	07-29-1999	Gadecke AG	

Examiner Signature	<i>Carr</i>	Date Considered	9/8/06
--------------------	-------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Mende Guide of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. *Enter Office that issued the document by the two-letter code (WIPO Standard ST.2). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 33 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. Including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

USSN 10/734,917
Docket No. PC25870A
Express Mail No. E5453992623US

FILED December 12, 2003

RECEIVED
CENTRAL FAX CENTER

SEP 20 2005

Approved for use through 04/30/2003, OMB 0651-0031
Trademark Office, U.S. DEPARTMENT OF COMMERCE
Information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

Sheet 1 of 2

Complete If Known

Application Number	10/734,917
Filing Date	12/12/2003
First Named Inventor	David J. Doolay
Art Unit	1621
Examiner Name	Unknown
Attorney Docket Number	PC2587OA

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Case No.*	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁴ (If Known)	Publication Date MM-DD-YYYY	Name of Person(s) or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
G	EP	0641330 B1	10-17-2001	R. B. Silverman, et al.		
	WO	98/17627 A1	04-30-1998	J. S. Bryans, et al.		
	WO	99/21824 A1	05-08-1999	J. S. Bryans, et al.		
	WO	00/76858 A2	12-21-2000	T. R. Bellotti, et al.		
	WO	01/28978 A1	04-26-2001	J. S. Bryans, et al.		
	WO	01/90052 A1	11-29-2001	J. S. Bryans, et al.		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with RCEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **1** Applicant's unique citation designation number (optional). **2** See Kinda Code of UPOG Patent Documents at www.wipo.int or [WIPO ST.14](http://www.wipo.int). Enter check mark (mark the document by the two-letter code (WIPO Standard ST.15). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **3** Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 18 if possible. **4** Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box

PTO/SB/068 (08-07)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/734,917
(use as many sheets as necessary)		Filing Date	December 12, 2003
Sheet	2	First Named Inventor	David J. Dooley
	of	Group Art Unit	1621
	2	Examiner Name	Unknown
		Attorney Docket Number	PC25870A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	
<i>J</i>		M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2213-2231; Vol. 9, No. 10	
		A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290	
		R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199	
		D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofascial pain syndrome" Current opinions in Rheumatology 2001;13:117-127	
		B. L. EHRENBURG, et al., "Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep", 1997, pp.A278-A279, Vol. 48	
		E. K. GUYMER, et al., "An approach to managing fibromyalgia" Medicine Today 2002:58-59; Vol. 3, No. 12	
		L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8	
		L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and ecg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2	
		I. SELAK, "Pregabalin (Pfizer)" Current opinion in investigational drugs, current drugs, Land, GB 2001:828-834; Vol. 2, No. 6	
		F. WOLFE, et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee" Arthritis Rheum 1990; 33:160-72	
<i>J</i>		M. B. YUNUS, "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217	

Examiner Signature	<i>Cel</i>	Date Considered	<i>7/08</i>
--------------------	------------	-----------------	-------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. This will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

Please type a plus sign (+) inside this box

PTO/SB/088 (08-00)

Approved for use through 10/31/2002. OMB 0851-0031
U. S. Patent and Trademark Office U. S. DEPARTMENT OF COMMERCE
is a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449B-PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/734,917
		Filing Date	December 12, 2003
		First Named Inventor	David J. Doolcy
		Group Art Unit	1621
		Examiner Name	Unknown
Sheet	1	of	1
		Attorney Docket Number	PC25870A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature	Co	Date Considered	8/8/4
-----------------------	----	--------------------	-------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313.**

ARBORE CONFIVED 7346222928

CENTRAL FAX CENTER

Customer No. 28880

SEP 20 2005

Confirmation No. 2382

PTO/SB/08A (08-09)

Approved for use through 07/31/2008. OMB 0851-0031

Under the Pennsylvania Protection Act of 1896, no person can proceed to a collection of affidavits for a trademark application.

Substitute for Form 1448/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MENT BY AN ERGONOMIST

Sheet 1 of 1

Complete if Known

Application Number	10/734,917
Filing Date	December 12, 2003
First Named Inventor	David James Dooley
Art Unit	1621
Examiner Name	Deborah D. Carr
Attorney Docket Number	PC 23870A

Sheet 1 of 1

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.87 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.